John DeMattei

Geschäftsführer bei OnKure, Inc.

Health Technology

Aktive Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
Anthony D. Piscopio	M	-	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	13 Jahre
Xuedong Liu	M	-	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	13 Jahre
R. Carruthers	M	66	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	5 Jahre
Nicholas A. Saccomano	M	65	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	-
Isaac Manke	M	47	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	3 Jahre
Andrew Phillips	M	53	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	3 Jahre
Guobao Zhao	M	-	OnKure, Inc. OnKure, Inc. BiotechnologyHealth Technology OnKure, Inc. engages in the discovery and development of epigenetic therapies for the treatment of cancer. It develops selective inhibitors of histone deacetylases in preclinical models of both hematological and solid tumor cancers. The company was founded by Xuedong Liu and Anthony D. Piscopio in April 2011 and is headquartered in Longmont, CO.	7 Jahre